- call +1-201-465-4211
- email sales@mrinsights.biz
The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
Scope of the Report:
At present, global investment concentrates in US and Europe, US takes 70% market share and Europe takes 25% market share. There are a few manufacturers in the world and the market concentration is high. The top5 (investment in Human Micobiome) companies are Vedanta, Seres Therapeutics, Second Genome, Rebiocix, ActoGeniX. The five companies occupy about 70% of the market share.
The global Human Microbiome market is valued at 190 million USD in 2018 and is expected to reach 620 million USD by the end of 2024, growing at a CAGR of 22.1% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Human Microbiome.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Human Microbiome market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Human Microbiome market by product type and applications/end industries.
Market Segment by Companies, this report covers
Vedanta
Seres Therapeutics
Second Genome
Rebiotix
ActoGeniX
Enterome BioScience
AvidBiotics
4D Pharma Research Ltd
Enterologics
Metabogen
Metabiomics
Ritter Pharmaceuticals
Osel
Symberix
Miomics
Symbiotix Biotherapies
MicroBiome Therapeutics LLC
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Gastrointestinal Tract Human Micobiome
Urogenital Tract Human Micobiome
Other
Market Segment by Applications, can be divided into
Treatment
Diagnosis
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Human Microbiome Market Overview
1.1 Product Overview and Scope of Human Microbiome
1.2 Classification of Human Microbiome by Types
1.2.1 Global Human Microbiome Revenue Comparison by Types (2019-2024)
1.2.2 Global Human Microbiome Revenue Market Share by Types in 2018
1.2.3 Gastrointestinal Tract Human Micobiome
1.2.4 Urogenital Tract Human Micobiome
1.2.5 Other
1.3 Global Human Microbiome Market by Application
1.3.1 Global Human Microbiome Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Treatment
1.3.3 Diagnosis
1.4 Global Human Microbiome Market by Regions
1.4.1 Global Human Microbiome Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) Human Microbiome Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Human Microbiome Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Human Microbiome Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) Human Microbiome Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Human Microbiome Status and Prospect (2014-2024)
1.5 Global Market Size of Human Microbiome (2014-2024)
2 Manufacturers Profiles
2.1 Vedanta
2.1.1 Business Overview
2.1.2 Human Microbiome Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Vedanta Human Microbiome Revenue, Gross Margin and Market Share (2017-2018)
2.2 Seres Therapeutics
2.2.1 Business Overview
2.2.2 Human Microbiome Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Seres Therapeutics Human Microbiome Revenue, Gross Margin and Market Share (2017-2018)
2.3 Second Genome
2.3.1 Business Overview
2.3.2 Human Microbiome Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Second Genome Human Microbiome Revenue, Gross Margin and Market Share (2017-2018)
2.4 Rebiotix
2.4.1 Business Overview
2.4.2 Human Microbiome Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Rebiotix Human Microbiome Revenue, Gross Margin and Market Share (2017-2018)
2.5 ActoGeniX
2.5.1 Business Overview
2.5.2 Human Microbiome Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 ActoGeniX Human Microbiome Revenue, Gross Margin and Market Share (2017-2018)
2.6 Enterome BioScience
2.6.1 Business Overview
2.6.2 Human Microbiome Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Enterome BioScience Human Microbiome Revenue, Gross Margin and Market Share (2017-2018)
2.7 AvidBiotics
2.7.1 Business Overview
2.7.2 Human Microbiome Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 AvidBiotics Human Microbiome Revenue, Gross Margin and Market Share (2017-2018)
2.8 4D Pharma Research Ltd
2.8.1 Business Overview
2.8.2 Human Microbiome Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 4D Pharma Research Ltd Human Microbiome Revenue, Gross Margin and Market Share (2017-2018)
2.9 Enterologics
2.9.1 Business Overview
2.9.2 Human Microbiome Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Enterologics Human Microbiome Revenue, Gross Margin and Market Share (2017-2018)
2.10 Metabogen
2.10.1 Business Overview
2.10.2 Human Microbiome Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Metabogen Human Microbiome Revenue, Gross Margin and Market Share (2017-2018)
2.11 Metabiomics
2.11.1 Business Overview
2.11.2 Human Microbiome Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Metabiomics Human Microbiome Revenue, Gross Margin and Market Share (2017-2018)
2.12 Ritter Pharmaceuticals
2.12.1 Business Overview
2.12.2 Human Microbiome Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Ritter Pharmaceuticals Human Microbiome Revenue, Gross Margin and Market Share (2017-2018)
2.13 Osel
2.13.1 Business Overview
2.13.2 Human Microbiome Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Osel Human Microbiome Revenue, Gross Margin and Market Share (2017-2018)
2.14 Symberix
2.14.1 Business Overview
2.14.2 Human Microbiome Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Symberix Human Microbiome Revenue, Gross Margin and Market Share (2017-2018)
2.15 Miomics
2.15.1 Business Overview
2.15.2 Human Microbiome Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Miomics Human Microbiome Revenue, Gross Margin and Market Share (2017-2018)
2.16 Symbiotix Biotherapies
2.16.1 Business Overview
2.16.2 Human Microbiome Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Symbiotix Biotherapies Human Microbiome Revenue, Gross Margin and Market Share (2017-2018)
2.17 MicroBiome Therapeutics LLC
2.17.1 Business Overview
2.17.2 Human Microbiome Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 MicroBiome Therapeutics LLC Human Microbiome Revenue, Gross Margin and Market Share (2017-2018)
3 Global Human Microbiome Market Competition, by Players
3.1 Global Human Microbiome Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Human Microbiome Players Market Share
3.2.2 Top 10 Human Microbiome Players Market Share
3.3 Market Competition Trend
4 Global Human Microbiome Market Size by Regions
4.1 Global Human Microbiome Revenue and Market Share by Regions
4.2 North America Human Microbiome Revenue and Growth Rate (2014-2019)
4.3 Europe Human Microbiome Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific Human Microbiome Revenue and Growth Rate (2014-2019)
4.5 South America Human Microbiome Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa Human Microbiome Revenue and Growth Rate (2014-2019)
5 North America Human Microbiome Revenue by Countries
5.1 North America Human Microbiome Revenue by Countries (2014-2019)
5.2 USA Human Microbiome Revenue and Growth Rate (2014-2019)
5.3 Canada Human Microbiome Revenue and Growth Rate (2014-2019)
5.4 Mexico Human Microbiome Revenue and Growth Rate (2014-2019)
6 Europe Human Microbiome Revenue by Countries
6.1 Europe Human Microbiome Revenue by Countries (2014-2019)
6.2 Germany Human Microbiome Revenue and Growth Rate (2014-2019)
6.3 UK Human Microbiome Revenue and Growth Rate (2014-2019)
6.4 France Human Microbiome Revenue and Growth Rate (2014-2019)
6.5 Russia Human Microbiome Revenue and Growth Rate (2014-2019)
6.6 Italy Human Microbiome Revenue and Growth Rate (2014-2019)
7 Asia-Pacific Human Microbiome Revenue by Countries
7.1 Asia-Pacific Human Microbiome Revenue by Countries (2014-2019)
7.2 China Human Microbiome Revenue and Growth Rate (2014-2019)
7.3 Japan Human Microbiome Revenue and Growth Rate (2014-2019)
7.4 Korea Human Microbiome Revenue and Growth Rate (2014-2019)
7.5 India Human Microbiome Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia Human Microbiome Revenue and Growth Rate (2014-2019)
8 South America Human Microbiome Revenue by Countries
8.1 South America Human Microbiome Revenue by Countries (2014-2019)
8.2 Brazil Human Microbiome Revenue and Growth Rate (2014-2019)
8.3 Argentina Human Microbiome Revenue and Growth Rate (2014-2019)
8.4 Colombia Human Microbiome Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue Human Microbiome by Countries
9.1 Middle East and Africa Human Microbiome Revenue by Countries (2014-2019)
9.2 Saudi Arabia Human Microbiome Revenue and Growth Rate (2014-2019)
9.3 UAE Human Microbiome Revenue and Growth Rate (2014-2019)
9.4 Egypt Human Microbiome Revenue and Growth Rate (2014-2019)
9.5 Nigeria Human Microbiome Revenue and Growth Rate (2014-2019)
9.6 South Africa Human Microbiome Revenue and Growth Rate (2014-2019)
10 Global Human Microbiome Market Segment by Type
10.1 Global Human Microbiome Revenue and Market Share by Type (2014-2019)
10.2 Global Human Microbiome Market Forecast by Type (2019-2024)
10.3 Gastrointestinal Tract Human Micobiome Revenue Growth Rate (2014-2024)
10.4 Urogenital Tract Human Micobiome Revenue Growth Rate (2014-2024)
10.5 Other Revenue Growth Rate (2014-2024)
11 Global Human Microbiome Market Segment by Application
11.1 Global Human Microbiome Revenue Market Share by Application (2014-2019)
11.2 Human Microbiome Market Forecast by Application (2019-2024)
11.3 Treatment Revenue Growth (2014-2019)
11.4 Diagnosis Revenue Growth (2014-2019)
12 Global Human Microbiome Market Size Forecast (2019-2024)
12.1 Global Human Microbiome Market Size Forecast (2019-2024)
12.2 Global Human Microbiome Market Forecast by Regions (2019-2024)
12.3 North America Human Microbiome Revenue Market Forecast (2019-2024)
12.4 Europe Human Microbiome Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific Human Microbiome Revenue Market Forecast (2019-2024)
12.6 South America Human Microbiome Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa Human Microbiome Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Human Microbiome Picture
Table Product Specifications of Human Microbiome
Table Global Human Microbiome and Revenue (Million USD) Market Split by Product Type
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
